A prominent voice in British reproductive policy has raised serious doubts about whether the UK's long-overdue legislative overhaul of surrogacy and reproductive law can be delivered through a single piece of legislation. Baroness Ruth Lynn Deech, the former chairwoman of the Human Fertilisation and Embryology Authority (HFEA), addressed the House of Lords last week with a clear message: Parliament must take the lead, and it must do so with care and scrutiny rather than convenience.

Two Reform Proposals — Two Very Different Challenges

At the core of Baroness Deech's argument is a distinction that has sometimes been obscured in the broader policy conversation. Two separate reform proposals are currently on the table. The first comes from the HFEA itself, its 2023 proposals to modernise the law governing fertility treatment. The second is the Law Commission's 2023 recommendations for a new surrogacy framework. Both are significant. Both are overdue. But Baroness Deech is emphatic that they are not the same thing.

On the HFEA's case for change, she offered a frank assessment of where the current regime falls short. "The HFEA itself acknowledges that, while much of the 1990 [Human Fertilisation and Embryology] Act remains fit for purpose, it has been updated by statute only once, in 2008, and now contains significant technical gaps, outdated consent rules and insufficient regulatory powers. The HFEA has made proposals for modernisation."

The framework governing surrogacy, meanwhile, has an even longer history of neglect. "The law governing surrogacy, the Surrogacy Arrangements Act 1985, was drafted for a world in which surrogacy was rare, poorly understood and feared."

Where the Lines Diverge

Baroness Deech described the HFEA's modernisation proposals as "an innovative, ethical, patient-centred system of reproductive law." The Law Commission's surrogacy recommendations, however, are a different matter in her view – "different" being the word she chose deliberately.

Her overall position has shifted over time, and she acknowledged as much. "As I have looked into this recently, I am less certain than I was that surrogacy and reproductive law can be resolved, certainly not in one statute. Parliament needs to take the lead in scrutiny." The implication is pointed. Combining two legally and ethically complex reform agendas into a single statute risks doing justice to neither. Surrogacy and reproductive law each carry their own histories, their own stakeholder communities, and their own unresolved ethical questions. Treating them as a single legislative bundle may create more problems than it solves.

The Emerging Frontier: Technologies the Law Hasn't Caught Up With

Beyond the existing gaps in legislation, Baroness Deech pointed to a cluster of emerging scientific and clinical developments that lawmakers will need to address proactively, rather than retrospectively. Her remarks in this area were among the most forward-looking of her address.

One issue is the 14-day rule, the longstanding limit on how long human embryos may be cultured outside the womb for research purposes. That limit is currently under review by the Nuffield Council on Bioethics, which is consulting with the public on whether it remains appropriate given advances in research capability.

A second development is in vitro-derived gametes, reproductive cells created not from eggs or sperm in the conventional sense, but by reprogramming other cell types, such as skin cells. Baroness Deech explained the parameters of the current legal position and its inadequacy. "In vitro-derived gametes are created by reprogramming other cells — for example, skin. Under current law, they could be used for research but not reproduction. The advantages are that they would eliminate the need for gamete donation, but they will need separate definition in the HFE Act, fresh consideration of the definition of parenthood and, of course, much more research."

The third area concerns stem cell-based embryo models, a field that sits at the intersection of biotechnology, ethics, and regulation. Baroness Deech described these as "lab-grown models made from human stem cells that mimic early stages of human embryonic development," and warned that they may be approaching the threshold where they could be considered real human embryos. She noted that a voluntary code of practice has been developed in Cambridge but argued that such an arrangement is insufficient for the long term. That code, she said, "needs to be embedded, with a view to developing a distinct method of regulating them."

The message running through each of these examples is consistent: regulation must anticipate scientific development, not chase it.

A Call for Parliamentary Oversight

Baroness Deech concluded with a concrete set of recommendations. She called on Parliament to modernise the Human Fertilisation and Embryology Act and to establish a Select Committee with a mandate to examine the HFEA's proposals in detail, covering the expansion of regulatory powers, simplification of consent rules, modernisation of donor information provisions, and the creation of a flexible framework capable of accommodating future scientific developments.

On the surrogacy side, the same Select Committee should treat the Law Commission's recommendations as a distinct and separate matter. "A Select Committee also needs to look at the Law Commission's surrogacy reforms as a second-order issue. As I said, I am not at all sure about integrating fertility and surrogacy law into a whole."

The speech adds a significant and experienced voice to what is becoming an increasingly urgent legislative conversation. The frameworks currently governing both surrogacy and reproductive law in the United Kingdom were written for eras that bear little resemblance to the clinical realities of 2026. Baroness Deech's intervention makes clear that the response to that outdatedness should be precise and deliberate, not rushed, not combined for administrative convenience, and not left to drift any further.